ORX-301
/ Oraxion Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 25, 2018
Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder.
(PubMed, Sci Rep)
- "We also show that ORX-301 penetrates the blood brain barrier and counteracts neurological impairment. These properties represent a substantial improvement and appear to overcome major limitations of presently available βCD-based therapy, demonstrating that this novel prodrug is a valuable alternative/complement for existing therapies."
Journal
1 to 1
Of
1
Go to page
1